Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131658) titled 'A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)' on Sept. 4.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
locally advanced, unresectable esophageal squamous cell carcinoma
Intervention:
durvalumab + dCRT:durvalumab
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2021-05-26
Target Sample Size: durvalumab + dCR...